Press releases
- Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
- Pulse Biosciences Enhances Executive Leadership Team
- Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
- Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
- Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
- Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
- Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
- Pulse Biosciences Announces Plans to Initiate a Rights Offering
- Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
- Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
More ▼
Key statistics
On Friday, Pulse Biosciences Inc (6L8:FRA) closed at 7.20, 103.39% above the 52 week low of 3.54 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.20 |
---|---|
High | 7.20 |
Low | 7.20 |
Bid | 7.10 |
Offer | 7.25 |
Previous close | 6.60 |
Average volume | 2.00 |
---|---|
Shares outstanding | 55.23m |
Free float | 16.36m |
P/E (TTM) | -- |
Market cap | 431.31m USD |
EPS (TTM) | -0.8152 USD |
Data delayed at least 15 minutes, as of May 17 2024 07:02 BST.
More ▼